Modulation of stress by imidazoline binding sites: Implications for psychiatric disorders

References

• Abu Ghazaleh H, Lalies MD, Husbands SM, Nutt DJ, Hudson AL. The effect of 1-(4,5-dihydro-1H-imidazol-2-yl) isoquinoline on monoamine release and turnover in the rat frontal cortex. Neurosci Lett 2007; 422: 109–113
   PubMed Web of Science ®Google Scholar
• Adell A, Biggs TA, Myers RD. Action of harman (1-methyl-beta-carboline) on the brain: Body temperature and in vivo efflux of 5-HT from hippocampus of the rat. Neuropharmacology 1996; 35: 1101–1107
   PubMed Web of Science ®Google Scholar
• Alahari SK, Lee JW, Juliano RL. Nischarin, a novel protein that interacts with the integrin alpha 5 subunit and inhibits cell migration. J Cell Biol 2000; 151: 1141–1154
   PubMed Web of Science ®Google Scholar
• Alahari SK. Nischarin inhibits Rac induced migration and invasion of epithelial cells by affecting signaling cascades involving PAK. Exp Cell Res 2003; 288: 415–424
   PubMed Web of Science ®Google Scholar
• Albores R, Neafsey EJ, Drucker G, Fields JZ, Collins MA. Mitochondrial respiratory inhibition by N-methylated beta-carboline derivatives structurally resembling N-methyl-4-phenylpyridine. Proc Natl Acad Sci USA 1990; 87: 9368–9372
   PubMed Web of Science ®Google Scholar
• Alexander SL, Irvine CH. The effect of the alpha-2-adrenergic agonist, clonidine, on secretion patterns and rates of adrenocorticotropic hormone and its secretagogues in the horse. J Neuroendocrinol 2000; 12: 874–880
   PubMed Web of Science ®Google Scholar
• Anderson NJ, Seif I, Nutt DJ, Hudson AL, Robinson ES. Autoradiographical distribution of imidazoline binding sites in monoamine oxidase A deficient mice. J Neurochem 2006; 96: 1551–1559
   PubMed Web of Science ®Google Scholar
• Arborelius L, Owens MJ, Plotsky PM, Nemeroff CB. The role of corticotropin-releasing factor in depression and anxiety disorders. J Endocrinol 1999; 160: 1–12
   PubMed Web of Science ®Google Scholar
• Aricioglu F, Altunbas H. Harmane induces anxiolysis and antidepressant-like effects in rats. Ann N Y Acad Sci 2003; 1009: 196–201
   PubMed Web of Science ®Google Scholar
• Atlas D. Identifying clonidine-displacing substance. Science 1994; 266: 462–464
   PubMed Web of Science ®Google Scholar
• Baker DG, West SA, Nicholson WE, Ekhator NN, Kasckow JW, Hill KK, Bruce AB, Orth DN, Geracioti TD, Jr. Serial CSF corticotropin-releasing hormone levels and adrenocortical activity in combat veterans with posttraumatic stress disorder. Am J Psychiatry 1999; 156: 585–588
   PubMed Web of Science ®Google Scholar
• Ballesteros J, Maeztu AI, Callado LF, Meana JJ, Gutierrez M. Specific binding of [(3)H]Ro 19-6327 (lazabemide) to monoamine oxidase B is increased in frontal cortex of suicide victims after controlling for age at death. Eur Neuropsychopharmacol 2008; 18: 55–61
   PubMed Web of Science ®Google Scholar
• Banki CM, Karmacsi L, Bissette G, Nemeroff CB. CSF corticotropin-releasing hormone and somatostatin in major depression: Response to antidepressant treatment and relapse. Eur Neuropsychopharmacol 1992; 2: 107–113
   PubMedGoogle Scholar
• Bissette G, Klimek V, Pan J, Stockmeier C, Ordway G. Elevated concentrations of CRF in the locus coeruleus of depressed subjects. Neuropsychopharmacology 2003; 28: 1328–1335
   PubMed Web of Science ®Google Scholar
• Bleck C, Wienbergen A, Rustenbeck I. Glucose dependence of imidazoline-induced insulin secretion: Different characteristics of two ATP-Sensitive K+ channel-blocking compounds. Diabetes 2004; 53(3)S135–S139
   Google Scholar
• Bornstein SR, Engeland WC, Ehrhart-Bornstein M, Herman JP. Dissociation of ACTH and glucocorticoids. Trends Endocrinol Metab 2008, 19:175–180
   PubMed Web of Science ®Google Scholar
• Bousquet P, Feldman J, Schwartz J. Central cardiovascular effects of alpha adrenergic drugs: Differences between catecholamines and imidazolines. J Pharmacol Exp Ther 1984; 230: 232–236
   PubMed Web of Science ®Google Scholar
• Bousquet P, Feldman J, Atlas D. An endogenous, non-catecholamine clonidine antagonist increases mean arterial blood pressure. Eur J Pharmacol 1986; 124: 167–170
   PubMed Web of Science ®Google Scholar
• Bousquet P, Greney H, Bruban V, Schann S, Ehrhardt JD, Monassier L, Feldman J. I(1) imidazoline receptors involved in cardiovascular regulation: Where are we and where are we going?. Ann NY Acad Sci 2003; 1009: 228–233
   PubMed Web of Science ®Google Scholar
• Bremner JD, Licinio J, Darnell A, Krystal JH, Owens MJ, Southwick SM, Nemeroff CB, Charney DS. Elevated CSF corticotropin-releasing factor concentrations in posttraumatic stress disorder. Am J Psychiatry 1997; 154: 624–629
   PubMed Web of Science ®Google Scholar
• Brown CM, MacKinnon AC, Redfern WS, Williams A, Linton C, Stewart M, Clague RU, Clark R, Spedding M. RS-45041-190: a selective, high-affinity ligand for I2 imidazoline receptors. Br J Pharmacol 1995; 116: 1737–1744
   PubMed Web of Science ®Google Scholar
• Burke SL, Malpas SC, Head GA. Effect of rilmenidine on the cadiovascular responses to stress in the conscious rabbit. J Auton Nerv Syst 1998; 72: 177–186
   PubMedGoogle Scholar
• Calogero AE, Bagdy G, Szemeredi K, Tartaglia ME, Gold PW, Chrousos GP. Mechanisms of serotonin receptor agonist-induced activation of the hypothalamic–pituitary–adrenal axis in the rat. Endocrinology 1990; 126: 1888–1894
   PubMed Web of Science ®Google Scholar
• Campbell WR, Potter DE. Potential role of imidazoline (I1) receptors in modulating aqueous humor dynamics. J Ocul Pharmacol 1994; 10: 393–402
   PubMedGoogle Scholar
• Carpenter WT, Jr, Bunney WE, Jr. Behavioral effects of cortisol in man. Semin Psychiatry 1971; 3: 421–434
   PubMedGoogle Scholar
• Chalmers J, Pilowsky P. Brainstem and bulbospinal neurotransmitter systems in the control of blood pressure. J Hypertens 1991; 9: 675–694
   PubMed Web of Science ®Google Scholar
• Chan SL, Morgan NG. Stimulation of insulin secretion by efaroxan may involve interaction with potassium channels. Eur J Pharmacol 1990; 176: 97–101
   PubMed Web of Science ®Google Scholar
• Christiansen L, Tan Q, Iachina M, Bathum L, Kruse TA, McGue M, Christensen K. Candidate gene polymorphisms in the serotonergic pathway: Influence on depression symptomatology in an elderly population. Biol Psychiatry 2007; 61: 223–230
   PubMed Web of Science ®Google Scholar
• Chrousos GP, Gold PW. The concepts of stress and stress system disorders. Overview of physical and behavioral homeostasis. Jama 1992; 267: 1244–1252
   PubMed Web of Science ®Google Scholar
• Cohen H, Zohar J, Gidron Y, Matar MA, Belkind D, Loewenthal U, Kozlovsky N, Kaplan Z. Blunted HPA axis response to stress influences susceptibility to posttraumatic stress response in rats. Biol Psychiatry 2006; 59: 1208–1218
   PubMed Web of Science ®Google Scholar
• Connor TJ, Kelly JP, Leonard BE. Forced swim test-induced neurochemical endocrine, and immune changes in the rat. Pharmacol Biochem Behav 1997; 58: 961–967
   PubMed Web of Science ®Google Scholar
• Cooper EJ, Hudson AL, Parker CA, Morgan NG. Effects of the beta-carbolines, harmane and pinoline, on insulin secretion from isolated human islets of Langerhans. Eur J Pharmacol 2003; 482: 189–196
   PubMed Web of Science ®Google Scholar
• Crowley GM. The enzymatic synthesis of 5′-phosphoribosylimidazoleacetic acid. J Biol Chem 1964; 239: 2593–2601
   PubMedGoogle Scholar
• Cummings S, Hinds D, Young WS, 3rd. Corticotropin-releasing factor mRNA increases in the inferior olivary complex during harmaline-induced tremor. Brain Res 1994; 660: 199–208
   PubMed Web of Science ®Google Scholar
• Dardonville C, Rozas I. Imidazoline binding sites and their ligands: an overview of the different chemical structures. Med Res Rev 2004; 24: 639–661
   PubMed Web of Science ®Google Scholar
• Day R, Nielsen JA, Korten A, Ernberg G, Dube KC, Gebhart J, Jablensky A, Leon C, Marsella A, Olatawura M, et al. Stressful life events preceding the acute onset of schizophrenia: A cross-national study from the World Health Organization. Cult Med Psychiatry 1987; 11: 123–205
   PubMed Web of Science ®Google Scholar
• De Bellis MD, Gold PW, Geracioti TD, Jr, Listwak SJ, Kling MA. Association of fluoxetine treatment with reductions in CSF concentrations of corticotropin-releasing hormone and arginine vasopressin in patients with major depression. Am J Psychiatry 1993; 150: 656–657
   PubMed Web of Science ®Google Scholar
• Diaz A, Mayet S, Dickenson AH. BU-224 produces spinal antinociception as an agonist at imidazoline I2 receptors. Eur J Pharmacol 1997; 333: 9–15
   PubMed Web of Science ®Google Scholar
• Dubrovsky B. The specificity of stress responses to different nocuous stimuli: Neurosteroids and depression. Brain Res Bull 2000; 51: 443–455
   PubMed Web of Science ®Google Scholar
• Durden DA, Nguyen TV, Boulton AA. Kinetics of intraventricularly injected trace amines and their deuterated isotopomers. Neurochem Res 1988; 13: 943–950
   PubMed Web of Science ®Google Scholar
• Edwards L, Fishman D, Horowitz P, Bourbon N, Kester M, Ernsberger P. The I1-imidazoline receptor in PC12 pheochromocytoma cells activates protein kinases C, extracellular signal-regulated kinase (ERK) and c-jun N-terminal kinase (JNK). J Neurochem 2001; 79: 931–940
   PubMed Web of Science ®Google Scholar
• Eglen RM, Hudson AL, Kendall DA, Nutt DJ, Morgan NG, Wilson VG, Dillon MP. Seeing through a glass darkly’: casting light on imidazoline ‘I’ sites. Trends Pharmacol Sci 1998; 19: 381–390
   PubMed Web of Science ®Google Scholar
• Ergene E, Schoener EP. Effects of harmane (1-methyl-beta-carboline) on neurons in the nucleus accumbens of the rat. Pharmacol Biochem Behav 1993; 44: 951–957
   PubMed Web of Science ®Google Scholar
• Ernsberger P. Arachidonic acid release from PC12 pheochromocytoma cells is regulated by I1-imidazoline receptors. J Auton Nerv Syst 1998; 72: 147–154
   PubMedGoogle Scholar
• Ernsberger P, Haxhiu MA. The I1-imidazoline-binding site is a functional receptor mediating vasodepression via the ventral medulla. Am J Physiol 1997; 273: R1572–R1579
   PubMed Web of Science ®Google Scholar
• Ernsberger P, Damon TH, Graff LM, Schafer SG, Christen MO. Moxonidine, a centrally acting antihypertensive agent, is a selective ligand for I1-imidazoline sites. J Pharmacol Exp Ther 1993; 264: 172–182
   PubMed Web of Science ®Google Scholar
• Ernsberger P, Graves ME, Graff LM, Zakieh N, Nguyen P, Collins LA, Westbrooks KL, Johnson GG. I1-imiddazoline receptors. Definition, characterization, distribution, and transmembrane signaling. Ann NY Acad Sci 1995; 763: 22–42
   PubMedGoogle Scholar
• Escriba PV, Sastre M, Wang H, Regunathan S, Reis DJ, Garcia-Sevilla JA. Immunodetection of putative imidazoline receptor proteins in the human and rat brain and other tissues. Neurosci Lett 1994; 178: 81–84
   PubMed Web of Science ®Google Scholar
• Esler M, Lux A, Jennings G, Hastings J, Socratous F, Lambert G. Rilmenidine sympatholytic activity preserves mental and orthostatic sympathetic response and epinephrine secretion. Arch Mal Coeur Vaiss 2004; 97: 786–792
   PubMedGoogle Scholar
• Fauvel JP, Najem R, Ryon B, Ducher M, Laville M. Effects of rilmenidine on stress-induced peak blood pressure and renal function. J Cardiovasc Pharmacol 1999; 34: 41–45
   PubMed Web of Science ®Google Scholar
• Felsen D, Ernsberger P, Meeley MP, Reis DJ. Clonidine displacing substance is biologically active on smooth muscle. Eur J Pharmacol 1987; 142: 453–455
   PubMed Web of Science ®Google Scholar
• Fernandes JF, Castellani O, Plese M. Biosynthesis of histamine ribotide and imidazoleacetate ribotide. Biochem Biophys Res Commun 1960; 3: 679–684
   PubMed Web of Science ®Google Scholar
• Finlay-Jones R, Brown GW. Types of stressful life event and the onset of anxiety and depressive disorders. Psychol Med 1981; 11: 803–815
   PubMed Web of Science ®Google Scholar
• Finn DP, Lalies MD, Harbuz MS, Jessop DS, Hudson AL, Nutt DJ. Imidazoline(2) (I(2)) binding site- and alpha(2)-adrenoceptor-mediated modulation of central noradrenergic and HPA axis function in control rats and chronically stressed rats with adjuvant-induced arthritis. Neuropharmacology 2002; 42: 958–965
   PubMed Web of Science ®Google Scholar
• Finn DP, Marti O, Harbuz MS, Valles A, Belda X, Marquez C, Jessop DS, Lalies MD, Armario A, Nutt DJ, Hudson AL. Behavioral, neuroendocrine and neurochemical effects of the imidazoline I2 receptor selective ligand BU224 in naive rats and rats exposed to the stress of the forced swim test. Psychopharmacology (Berl) 2003; 167: 195–202
   PubMed Web of Science ®Google Scholar
• Finn DP, Hudson AL, Kinoshita H, Coventry TL, Jessop DS, Nutt DJ, Harbuz MS. Imidazoline 2 (I2) receptor- and alpha2-adrenoceptor-mediated modulation of hypothalamic–pituitary–adrenal axis activity in control and acute restraint stressed rats. J Psychopharmacol 2004; 18: 47–53
   PubMed Web of Science ®Google Scholar
• Fossey MD, Lydiard RB, Ballenger JC, Laraia MT, Bissette G, Nemeroff CB. Cerebrospinal fluid corticotropin-releasing factor concentrations in patients with anxiety disorders and normal comparison subjects. Biol Psychiatry 1996; 39: 703–707
   PubMed Web of Science ®Google Scholar
• Friedrich VL, Jr, Martinelli GP, Prell GD, Holstein GR. Distribution and cellular localization of imidazoleacetic acid-ribotide, an endogenous ligand at imidazol(in)e and adrenergic receptors, in rat brain. J Chem Neuroanat 2007; 33: 53–64
   PubMed Web of Science ®Google Scholar
• Garcia-Sevilla JA, Escriba PV, Guimon J. Imidazoline receptors and human brain disorders. Ann NY Acad Sci 1999; 881: 392–409
   PubMed Web of Science ®Google Scholar
• Garcia-Sevilla JA, Escriba PV, Sastre M, Walzer C, Busquets X, Jaquet G, Reis DJ, Guimon J. Immunodetection and quantitation of imidazoline receptor proteins in platelets of patients with major depression and in brains of suicide victims. Arch Gen Psychiatry 1996; 53: 803–810
   PubMed Web of Science ®Google Scholar
• Ghadirian AM, Marcovitz S, Pearson Murphy BE. A case of seasonal bipolar disorder exacerbated by Cushing's disease. Compr Psychiatry 2005; 46: 155–158
   PubMed Web of Science ®Google Scholar
• Ghadirian AM, Engelsmann F, Dhar V, Filipini D, Keller R, Chouinard G, Murphy BE. The psychotropic effects of inhibitors of steroid biosynthesis in depressed patients refractory to treatment. Biol Psychiatry 1995; 37: 369–375
   PubMed Web of Science ®Google Scholar
• Gibbons JL, McHugh Pr. Plasma cortisol in depressive illness. J Psychiatr Res 1962; 1: 162–171
   PubMed Web of Science ®Google Scholar
• Giraldi T, De Vanna M, Malagoli M, Tuveri G, Sutto K, Schillani G, Grassi L. Mental adaptation to cancer: Depression and blood platelet monoamine oxidase activity in breast cancer patients. Anticancer Res 2007; 27: 1715–1719
   PubMed Web of Science ®Google Scholar
• Glennon RA, Dukat M, Grella B, Hong S, Costantino L, Teitler M, Smith C, Egan C, Davis K, Mattson MV. Binding of beta-carbolines and related agents at serotonin (5-HT(2) and 5-HT(1A)), dopamine (D(2)) and benzodiazepine receptors. Drug Alcohol Depend 2000; 60: 121–132
   PubMed Web of Science ®Google Scholar
• Glue P, Wilson S, Campling GM, Knightly M, Franklin M, Cowen PJ, Nutt DJ. Alpha-2-adrenoceptor control of cortisol and ACTH in normal volunteers: Preliminary open trial of the effects of acute and chronic idazoxan. Psychoneuroendocrinology 1992; 17: 261–266
   PubMed Web of Science ®Google Scholar
• Golanov EV, Reis DJ. A role for KATP+-channels in mediating the elevations of cerebral blood flow and arterial pressure by hypoxic stimulation of oxygen-sensitive neurons of rostral ventrolateral medulla. Brain Res 1999; 827: 210–214
   PubMed Web of Science ®Google Scholar
• Gollan JK, Lee R, Coccaro EF. Developmental psychopathology and neurobiology of aggression. Dev Psychopathol 2005; 17: 1151–1171
   PubMed Web of Science ®Google Scholar
• Gong ZH, Li YF, Zhao N, Yang HJ, Su RB, Luo ZP, Li J. Anxiolytic effect of agmatine in rats and mice. Eur J Pharmacol 2006; 550: 112–116
   PubMed Web of Science ®Google Scholar
• Gothert M, Molderings GJ, Fink K, Schlicker E. Alpha 2-adrenoceptor-independent inhibition by imidazolines and guanidines of noradrenaline release from peripheral, but not central noradrenergic neurons. Ann NY Acad Sci 1995; 763: 405–419
   PubMedGoogle Scholar
• Greden JF, Gardner R, King D, Grunhaus L, Carroll BJ, Kronfol Z. Dexamethasone suppression tests in antidepressant treatment of melancholia. The process of normalization and test-retest reproducibility. Arch Gen Psychiatry 1983; 40: 493–500
   PubMed Web of Science ®Google Scholar
• Grigoriadis DE. The corticotropin-releasing factor receptor: A novel target for the treatment of depression and anxiety-related disorders. Expert Opin Ther Targets 2005; 9: 651–684
   PubMed Web of Science ®Google Scholar
• Gruen R, Baron M. Stressful life events and schizophrenia. Relation to illness onset and family history. Neuropsychobiology 1984; 12: 206–208
   PubMed Web of Science ®Google Scholar
• Halaris A, Piletz JE. Imidazoline receptors: Possible involvement in the pathophysiology and treatment of depression. Hum Psychopharmacol 2001; 16: 65–69
   PubMed Web of Science ®Google Scholar
• Halaris A, Piletz JE. Relevance of imidazoline receptors and agmatine to psychiatry: A decade of progress. Ann NY Acad Sci 2003; 1009: 1–20
   PubMed Web of Science ®Google Scholar
• Halaris A, Zhu H, Ali J, Nasrallah A, Lindsay De Vane C, Piletz JE. Down-regulation of platelet imidazoline-1-binding sites after bupropion treatment. Int J Neuropsychopharmacol 2002; 5: 37–46
   PubMed Web of Science ®Google Scholar
• Head GA, Burke SL. Sympathetic responses to stress and rilmenidine in 2K1C rabbits: Evidence of enhanced nonvascular effector mechanism. Hypertension 2004; 43: 636–642
   PubMed Web of Science ®Google Scholar
• Heim C, Plotsky PM, Nemeroff CB. Importance of studying the contributions of early adverse experience to neurobiological findings in depression. Neuropsychopharmacology 2004; 29: 641–648
   PubMed Web of Science ®Google Scholar
• Herraiz T, Chaparro C. Human monoamine oxidase is inhibited by tobacco smoke: Beta-carboline alkaloids act as potent and reversible inhibitors. Biochem Biophys Res Commun 2005; 326: 378–386
   PubMed Web of Science ®Google Scholar
• Holsboer F. The corticosteroid receptor hypothesis of depression. Neuropsychopharmacology 2000; 23: 477–501
   PubMed Web of Science ®Google Scholar
• Holt A, Wieland B, Baker GB. Allosteric modulation of semicarbazide-sensitive amine oxidase activities in vitro by imidazoline receptor ligands. Br J Pharmacol 2004; 143: 495–507
   PubMed Web of Science ®Google Scholar
• Hudson CJ, Young LT, Li PP, Warsh JJ. CNS signal transduction in the pathophysiology and pharmacotherapy of affective disorders and schizophrenia. Synapse 1993; 13: 278–293
   PubMed Web of Science ®Google Scholar
• Hudson AL, Chapleo CB, Lewis JW, Husbands S, Grivas K, Mallard NJ, Nutt DJ. Identification of ligands selective for central I2-imidazoline binding sites. Neurochem Int 1997; 30: 47–53
   PubMed Web of Science ®Google Scholar
• Hudson AL, Gough R, Tyacke R, Lione L, Lalies M, Lewis J, Husbands S, Knight P, Murray F, Hutson P, Nutt DJ. Novel selective compounds for the investigation of imidazoline receptors. Ann NY Acad Sci 1999; 881: 81–91
   PubMed Web of Science ®Google Scholar
• Ising M, Holsboer F. CRH-sub-1 receptor antagonists for the treatment of depression and anxiety. Exp Clin Psychopharmacol 2007; 15: 519–528
   PubMed Web of Science ®Google Scholar
• Isolan LR, Zeni CP, Mezzomo K, Blaya C, Kipper L, Heldt E, Manfro GG. Behavioral inhibition and history of childhood anxiety disorders in Brazilian adult patients with panic disorder and social anxiety disorder. Rev Bras Psiquiatr 2005; 27: 97–100
   PubMedGoogle Scholar
• Ivanov TR, Zhu H, Regunathan S, Reis DJ, Dontenwill M, Vonthron C, Bousquet P, Piletz JE. Co-detection by two imidazoline receptor protein antisera of a novel 85 kilodalton protein. Biochem Pharmacol 1998; 55: 649–655
   PubMed Web of Science ®Google Scholar
• Joca SR, Ferreira FR, Guimaraes FS. Modulation of stress consequences by hippocampal monoaminergic, glutamatergic and nitrergic neurotransmitter systems. Stress 2007; 10: 227–249
   PubMed Web of Science ®Google Scholar
• Jolkkonen J, Lepola U, Bissette G, Nemeroff C, Riekkinen P. CSF corticotropin-releasing factor is not affected in panic disorder. Biol Psychiatry 1993; 33: 136–138
   PubMed Web of Science ®Google Scholar
• Jope RS, Williams MB. Lithium and brain signal transduction systems. Biochem Pharmacol 1994; 47: 429–441
   PubMed Web of Science ®Google Scholar
• Judge SJ, Ingram CD, Gartside SE. Moderate differences in circulating corticosterone alter receptor-mediated regulation of 5-hydroxytryptamine neuronal activity. J Psychopharmacol 2004; 18: 475–483
   PubMed Web of Science ®Google Scholar
• Kageyama K, Tozawa F, Horiba N, Watanobe H, Suda T. Serotonin stimulates corticotropin-releasing factor gene expression in the hypothalamic paraventricular nucleus of conscious rats. Neurosci Lett 1998; 243: 17–20
   PubMed Web of Science ®Google Scholar
• Kalin NH, Shelton SE, Turner JG. Effects of beta-carboline on fear-related behavioral and neurohormonal responses in infant rhesus monkeys. Biol Psychiatry 1992; 31: 1008–1019
   PubMed Web of Science ®Google Scholar
• Kendler KS, Karkowski-Shuman L. Stressful life events and genetic liability to major depression: Genetic control of exposure to the environment?. Psychol Med 1997; 27: 539–547
   PubMed Web of Science ®Google Scholar
• Kendler KS, Karkowski LM, Prescott CA. Causal relationship between stressful life events and the onset of major depression. Am J Psychiatry 1999; 156: 837–841
   PubMed Web of Science ®Google Scholar
• Kim H, Sablin SO, Ramsay RR. Inhibition of monoamine oxidase A by beta-carboline derivatives. Arch Biochem Biophys 1997; 337: 137–142
   PubMed Web of Science ®Google Scholar
• King PR, Gundlach AL, Louis WJ. Quantitative autoradiographic localization in rat brain of alpha 2-adrenergic and non-adrenergic I-receptor binding sites labelled by [3H]rilmenidine. Brain Res 1995; 675: 264–278
   PubMed Web of Science ®Google Scholar
• de Kloet CS, Vermetten E, Heijnen CJ, Geuze E, Lentjes EG, Westenberg HG. Enhanced cortisol suppression in response to dexamethasone administration in traumatized veterans with and without posttraumatic stress disorder. Psychoneuroendocrinology 2007; 32: 215–226
   PubMed Web of Science ®Google Scholar
• de Kloet CS, Vermetten E, Geuze E, Lentjes EG, Heijnen CJ, Stalla GK, Westenberg HG. Elevated plasma corticotrophin-releasing hormone levels in veterans with posttraumatic stress disorder. Prog Brain Res 2008; 167: 287–291
   PubMed Web of Science ®Google Scholar
• Krishnan KR, Doraiswamy PM, Lurie SN, Figiel GS, Husain MM, Boyko OB, Ellinwood EH, Jr, Nemeroff CB. Pituitary size in depression. J Clin Endocrinol Metab 1991; 72: 256–259
   PubMed Web of Science ®Google Scholar
• Lahniers CE, White K. Changes in environmental life events and their relationship to psychiatric hospital admissions. J Nerv Ment Dis 1976; 163: 154–158
   PubMed Web of Science ®Google Scholar
• Laubie M, Poignant JC, Scuvee-Moreau J, Dabire H, Dresse A, Schmitt H. Pharmacological properties of (N-dicyclopropylmethyl) amino-2-oxazoline (S 3341), an alpha-2 adrenoceptor agonist. J Pharmacol 1985; 16: 259–278
   PubMedGoogle Scholar
• Lavinsky D, Arteni NS, Netto CA. Agmatine induces anxiolysis in the elevated plus maze task in adult rats. Behav Brain Res 2003; 141: 19–24
   PubMed Web of Science ®Google Scholar
• Li D, He L. Meta-study on association between the monoamine oxidase A gene (MAOA) and schizophrenia. Am J Med Genet B Neuropsychiatr Genet 2007
   Google Scholar
• Lione LA, Nutt DJ, Hudson AL. Characterisation and localisation of [3H]2-(2-benzofuranyl)-2-imidazoline binding in rat brain: A selective ligand for imidazoline I2 receptors. Eur J Pharmacol 1998; 353: 123–135
   PubMed Web of Science ®Google Scholar
• Liposits Z, Uht RM, Harrison RW, Gibbs FP, Paull WK, Bohn MC. Ultrastructural localization of glucocorticoid receptor (GR) in hypothalamic paraventricular neurons synthesizing corticotropin releasing factor (CRF). Histochemistry 1987; 87: 407–412
   PubMedGoogle Scholar
• Li YF, Gong ZH, Cao JB, Wang HL, Luo ZP, Li J. Antidepressant-like effect of agmatine and its possible mechanism. Eur J Pharmacol 2003; 469: 81–88
   PubMed Web of Science ®Google Scholar
• MacInnes N, Handley SL. Autoradiographic localisation of [3H]2-BFI imidazoline I2 binding sites in mouse brain. Eur J Pharmacol 2005; 516: 139–144
   PubMed Web of Science ®Google Scholar
• MacKinnon AC, Redfern WS, Brown CM. [3H]-RS-45041-190: A selective high-affinity radioligand for I2 imidazoline receptors. Br J Pharmacol 1995; 116: 1729–1736
   PubMed Web of Science ®Google Scholar
• Manji HK. G proteins: Implications for psychiatry. Am J Psychiatry 1992; 149: 746–760
   PubMed Web of Science ®Google Scholar
• Marti O, Armario A. Anterior pituitary response to stress: Time-related changes and adaptation. Int J Dev Neurosci 1998; 16: 241–260
   PubMed Web of Science ®Google Scholar
• Mayer KH, Stamler J, Dyer A, Freinkel N, Stamler R, Berkson DM, Farber B. Epidemiologic findings on the relationship of time of day and time since last meal to glucose tolerance. Diabetes 1976; 25: 936–943
   PubMed Web of Science ®Google Scholar
• McEwen BS. Physiology and neurobiology of stress and adaptation: central role of the brain. Physiol Rev 2007; 87: 873–904
   PubMed Web of Science ®Google Scholar
• Meana JJ, Herrera-Marschitz M, Goiny M, Silveira R. Modulation of catecholamine release by alpha 2-adrenoceptors and I1-imidazoline receptors in rat brain. Brain Res 1997; 744: 216–226
   PubMed Web of Science ®Google Scholar
• Merali Z, Du L, Hrdina P, Palkovits M, Faludi G, Poulter MO, Anisman H. Dysregulation in the suicide brain: mRNA expression of corticotropin-releasing hormone receptors and GABA(A) receptor subunits in frontal cortical brain region. J Neurosci 2004; 24: 1478–1485
   PubMed Web of Science ®Google Scholar
• Mest HJ, Raap A, Schloos J, Treinies I, Paal M, Giese U, Koivisto V. Glucose-induced insulin secretion is potentiated by a new imidazoline compound. Naunyn Schmiedebergs Arch Pharmacol 2001; 364: 47–52
   PubMed Web of Science ®Google Scholar
• Michelson D, Galliven E, Hill L, Demitrack M, Chrousos G, Gold P. Chronic imipramine is associated with diminished hypothalamic–pituitary–adrenal axis responsivity in healthy humans. J Clin Endocrinol Metab 1997; 82: 2601–2606
   PubMed Web of Science ®Google Scholar
• Modell S, Yassouridis A, Huber J, Holsboer F. Corticosteroid receptor function is decreased in depressed patients. Neuroendocrinology 1997; 65: 216–222
   PubMed Web of Science ®Google Scholar
• Molderings GJ, Likungu J, Jakschik J, Gothert M. Presynaptic imidazoline receptors and non-adrenoceptor [3H]-idazoxan binding sites in human cardiovascular tissues. Br J Pharmacol 1997; 122: 43–50
   PubMed Web of Science ®Google Scholar
• Morgan NG, Chan SL. Imidazoline binding sites in the endocrine pancreas: Can they fulfil their potential as targets for the development of new insulin secretagogues?. Curr Pharm Des 2001; 7: 1413–1431
   PubMed Web of Science ®Google Scholar
• Morgan NG, Chan SL, Mourtada M, Monks LK, Ramsden CA. Imidazolines and pancreatic hormone secretion. Ann NY Acad Sci 1999; 881: 217–228
   PubMed Web of Science ®Google Scholar
• Mourtada M, Smith SA, Morgan NG. Insulin secretagogues with an imidazoline structure inhibit arginine-induced secretion from isolated glucagon secretion from isolated rat islets of Langerhans. Biochem Biophys Res Commun 1997; 236: 162–166
   PubMed Web of Science ®Google Scholar
• Muller WE, Fehske KJ, Borbe HO, Wollert U, Nanz C, Rommelspacher H. On the neuropharmacology of harmane and other beta-carbolines. Pharmacol Biochem Behav 1981; 14: 693–699
   PubMed Web of Science ®Google Scholar
• Munoz-Hoyos A, Fernandez-Garcia JM, Molina-Carballo A, Macias M, Escames G, Ruiz-Cosano C, Acuna-Castroviejo D. Effect of clonidine on plasma ACTH, cortisol and melatonin in children. J Pineal Res 2000; 29: 48–53
   PubMed Web of Science ®Google Scholar
• Musgrave IF, Badoer E. Harmane produces hypotension following microinjection into the RVLM: Possible role of I(1)-imidazoline receptors. Br J Pharmacol 2000; 129: 1057–1059
   PubMed Web of Science ®Google Scholar
• Nash MW, Sugden K, Huezo-Diaz P, Williamson R, Sterne A, Purcell S, Sham PC, Craig IW. Association analysis of monoamine genes with measures of depression and anxiety in a selected community sample of siblings. Am J Med Genet B Neuropsychiatr Genet 2005; 135: 33–37
   Google Scholar
• Nemeroff CB, Owens MJ, Bissette G, Andorn AC, Stanley M. Reduced corticotropin releasing factor binding sites in the frontal cortex of suicide victims. Arch Gen Psychiatry 1988; 45: 577–579
   PubMed Web of Science ®Google Scholar
• Nutt DJ, French N, Handley S, Hudson A, Husbands S, Jackson H, Jordan S, Lalies MD, Lewis J, Lione L, et al. Functional studies of specific imidazoline-2 receptor ligands. Ann NY Acad Sci 1995; 763: 125–139
   PubMedGoogle Scholar
• Nutt DJ, Lalies MD, Lione LA, Hudson AL. Noradrenergic mechanisms in the prefrontal cortex. J Psychopharmacol 1997; 11: 163–168
   PubMed Web of Science ®Google Scholar
• O'Neill MF, Osborne DJ, Woodhouse SM, Conway MW. Selective imidazoline I2 ligands do not show antidepressant-like activity in the forced swim test in mice. J Psychopharmacol 2001; 15: 18–22
   PubMed Web of Science ®Google Scholar
• Olmos G, Gabilondo AM, Miralles A, Escriba PV, Garcia-Sevilla JA. Chronic treatment with the monoamine oxidase inhibitors clorgyline and pargyline down-regulates non-adrenoceptor [3H]-idazoxan binding sites in the rat brain. Br J Pharmacol 1993; 108: 597–603
   PubMed Web of Science ®Google Scholar
• Olmos G, Alemany R, Boronat MA, Garcia-Sevilla JA. Pharmacologic and molecular discrimination of I2-imidazoline receptor subtypes. Ann NY Acad Sci 1999; 881: 144–160
   PubMed Web of Science ®Google Scholar
• Pacak K. Stressor-specific activation of the hypothalamic–pituitary–adrenocortical axis. Physiol Res 2000; 49(Suppl 1)S11–S17
   PubMed Web of Science ®Google Scholar
• Pacak K, Palkovits M. Stressor specificity of central neuroendocrine responses: Implications for stress-related disorders. Endocr Rev 2001; 22: 502–548
   PubMed Web of Science ®Google Scholar
• Pacheco MA, Stockmeier C, Meltzer HY, Overholser JC, Dilley GE, Jope RS. Alterations in phosphoinositide signaling and G-protein levels in depressed suicide brain. Brain Res 1996; 723: 37–45
   PubMed Web of Science ®Google Scholar
• Pariante CM, Papadopoulos AS, Poon L, Cleare AJ, Checkley SA, English J, Kerwin RW, Lightman S. Four days of citalopram increase suppression of cortisol secretion by prednisolone in healthy volunteers. Psychopharmacology (Berl) 2004; 177: 200–206
   PubMed Web of Science ®Google Scholar
• Parini A, Moudanos CG, Pizzinat N, Lanier SM. The elusive family of imidazoline binding sites. Trends Pharmacol Sci 1996; 17: 13–16
   PubMed Web of Science ®Google Scholar
• Parker CA, Hudson AL, Nutt DJ, Dillon MP, Eglen RM, Crosby J. Isolation of RP-HPLC pure clonidine-displacing substance from NG108-15 cells. Eur J Pharmacol 2000; 387: 27–30
   PubMed Web of Science ®Google Scholar
• Parker KJ, Schatzberg AF, Lyons DM. Neuroendocrine aspects of hypercortisolism in major depression. Horm Behav 2003; 43: 60–66
   PubMed Web of Science ®Google Scholar
• Parker CA, Anderson NJ, Robinson ES, Price R, Tyacke RJ, Husbands SM, Dillon MP, Eglen RM, Hudson AL, Nutt DJ, Crump MP, Crosby J. Harmane and harmalan are bioactive components of classical clonidine-displacing substance. Biochemistry 2004; 43: 16385–16392
   PubMed Web of Science ®Google Scholar
• Paterson L.M., Tyacke R.J., Robinson E.S., Nutt D.J., Hudson A.L. In vitro and in vivo effect of BU99006 (5-isothiocyanato-2-benzofuranyl-2-imidazoline) on I(2) binding in relation to MAO: Evidence for two distinct I(2) binding sites. Neuropharmacology 2006; 52: 395–404
   PubMed Web of Science ®Google Scholar
• Piletz J, Baker R, Halaris A. Platelet imidazoline receptors as state marker of depressive symptomatology. J Psychiatr Res 2008; 42: 41–49
   PubMed Web of Science ®Google Scholar
• Piletz JE, Halaris A, Saran A, Marler MR. Desipramine lowers tritiated para-aminoclonidine binding in platelets of depressed patients. Arch Gen Psychiatry 1991; 48: 813–820
   PubMed Web of Science ®Google Scholar
• Piletz JE, Halaris A, Ernsberger PR. Psychopharmacology of imidazoline and alpha 2-adrenergic receptors: Implications for depression. Crit Rev Neurobiol 1994; 9: 29–66
   PubMedGoogle Scholar
• Piletz JE, Halaris A, Nelson J, Qu Y, Bari M. Platelet I1-imidazoline binding sites are elevated in depression but not generalized anxiety disorder. J Psychiatr Res 1996a; 30: 147–168
   PubMed Web of Science ®Google Scholar
• Piletz JE, Halaris AE, Chikkala D, Qu Y. Platelet I1-imidazoline binding sites are decreased by two dissimilar antidepressant agents in depressed patients. J Psychiatr Res 1996b; 30: 169–184
   PubMed Web of Science ®Google Scholar
• Piletz JE, Ivanov TR, Sharp JD, Ernsberger P, Chang CH, Pickard RT, Gold G, Roth B, Zhu H, Jones JC, Baldwin J, Reis DJ. Imidazoline receptor antisera-selected (IRAS) cDNA: Cloning and characterization. DNA Cell Biol 2000; 19: 319–329
   PubMed Web of Science ®Google Scholar
• Pineda J, Ugedo L, Garcia-Sevilla JA. Stimulatory effects of clonidine, cirazoline and rilmenidine on locus coeruleus noradrenergic neurones: Possible involvement of imidazoline-preferring receptors. Naunyn Schmiedebergs Arch Pharmacol 1993; 348: 134–140
   PubMed Web of Science ®Google Scholar
• Plotsky PM. Facilitation of immunoreactive corticotropin-releasing factor secretion into the hypophysial-portal circulation after activation of catecholaminergic pathways or central norepinephrine injection. Endocrinology 1987; 121: 924–930
   PubMed Web of Science ®Google Scholar
• Popma A, Doreleijers TA, Jansen LM, Van Goozen SH, Van Engeland H, Vermeiren R. The diurnal cortisol cycle in delinquent male adolescents and normal controls. Neuropsychopharmacology 2007; 32: 1622–1628
   PubMed Web of Science ®Google Scholar
• Prell GD, Martinelli GP, Holstein GR, Matulic-Adamic J, Watanabe KA, Chan SL, Morgan NG, Haxhiu MA, Ernsberger P. Imidazoleacetic acid-ribotide: An endogenous ligand that stimulates imidazol(in)e receptors. Proc Natl Acad Sci USA 2004; 101: 13677–13682
   PubMed Web of Science ®Google Scholar
• Raddatz R, Parini A, Lanier SM. Imidazoline/guanidinium binding domains on monoamine oxidases. Relationship to subtypes of imidazoline-binding proteins and tissue-specific interaction of imidazoline ligands with monoamine oxidase B. J Biol Chem 1995; 270: 27961–27968
   PubMed Web of Science ®Google Scholar
• Reddig PJ, Xu D, Juliano RL. Regulation of p21-activated kinase-independent Rac1 signal transduction by nischarin. J Biol Chem 2005; 280: 30994–31002
   PubMed Web of Science ®Google Scholar
• Regunathan S, Meeley MP, Reis DJ. Clonidine-displacing substance from bovine brain binds to imidazoline receptors and releases catecholamines in adrenal chromaffin cells. Mol Pharmacol 1991; 40: 884–888
   PubMed Web of Science ®Google Scholar
• Reis DJ, Regunathan S. Is agmatine a novel neurotransmitter in brain?. Trends Pharmacol Sci 2000; 21: 187–193
   PubMed Web of Science ®Google Scholar
• Reis DJ, Piletz JE. The imidazoline receptor in control of blood pressure by clonidine and allied drugs. Am J Physiol 1997; 273: R1569–R1571
   Google Scholar
• Renouard A, Widdowson PS, Cordi A. [3H]-idazoxan binding to rabbit cerebral cortex recognises multiple imidazoline I2-type receptors: Pharmacological characterization and relationship to monoamine oxidase. Br J Pharmacol 1993; 109: 625–631
   PubMed Web of Science ®Google Scholar
• Ribeiro SC, Tandon R, Grunhaus L, Greden JF. The DST as a predictor of outcome in depression: A meta-analysis. Am J Psychiatry 1993; 150: 1618–1629
   PubMed Web of Science ®Google Scholar
• Robinson ES, Tyacke RJ, Nutt DJ, Hudson AL. Distribution of [(3)H]BU224, a selective imidazoline I(2) binding site ligand, in rat brain. Eur J Pharmacol 2002; 450: 55–60
   PubMed Web of Science ®Google Scholar
• Rommelspacher H, May T, Salewski B. Harman (1-methyl-beta-carboline) is a natural inhibitor of monoamine oxidase type A in rats. Eur J Pharmacol 1994; 252: 51–59
   PubMed Web of Science ®Google Scholar
• Rubin RT, Phillips JJ, McCracken JT, Sadow TF. Adrenal gland volume in major depression: Relationship to basal and stimulated pituitary–adrenal cortical axis function. Biol Psychiatry 1996; 40: 89–97
   PubMed Web of Science ®Google Scholar
• Ruiz-Durantez E, Ruiz-Ortega JA, Pineda J, Ugedo L. Stimulatory effect of harmane and other beta-carbolines on locus coeruleus neurons in anaesthetized rats. Neurosci Lett 2001; 308: 197–200
   PubMed Web of Science ®Google Scholar
• Ruiz-Ortega JA, Ugedo L. The stimulatory effect of clonidine on locus coeruleus neurons of rats with inactivated alpha 2-adrenoceptors: Involvement of imidazoline receptors located in the nucleus paragigantocellularis. Naunyn Schmiedebergs Arch Pharmacol 1997; 355: 288–294
   PubMed Web of Science ®Google Scholar
• Sanchez-Blazquez P, Boronat MA, Olmos G, Garcia-Sevilla JA, Garzon J. Activation of I(2)-imidazoline receptors enhances supraspinal morphine analgesia in mice: a model to detect agonist and antagonist activities at these receptors. Br J Pharmocol 2000; 130: 146–152
   PubMed Web of Science ®Google Scholar
• Samad N, Perveen T, Haider S, Haleem MA, Haleem DJ. Inhibition of restraint-induced neuroendocrine and serotonergic responses by buspirone in rats. Pharmacol Rep 2006; 58: 636–642
   PubMed Web of Science ®Google Scholar
• Sano H, Liu SC, Lane WS, Piletz JE, Lienhard GE. Insulin receptor substrate 4 associates with the protein IRAS. J Biol Chem 2002; 277: 19439–19447
   PubMed Web of Science ®Google Scholar
• Saphier D, Feldman S. Catecholaminergic projections to tuberoinfundibular neurones of the paraventricular nucleus: II. Effects of stimulation of the ventral noradrenergic ascending bundle: Evidence for cotransmission. Brain Res Bull 1989; 23: 397–404
   PubMed Web of Science ®Google Scholar
• Saphier D, Welch JE. Central stimulation of adrenocortical secretion by 5-hydroxytryptamine1 A agonists is mediated by sympathomedullary activation. J Pharmacol Exp Ther 1994; 270: 905–917
   PubMed Web of Science ®Google Scholar
• Saphier D, Farrar GE, Welch JE. Differential inhibition of stress-induced adrenocortical responses by 5-HT1A agonists and by 5-HT2 and 5-HT3 antagonists. Psychoneuroendocrinology 1995; 20: 239–257
   PubMed Web of Science ®Google Scholar
• Sapolsky RM, Romero LM, Munck AU. How do glucocorticoids influence stress responses? Integrating permissive, suppressive, stimulatory, and preparative actions. Endocr Rev 2000; 21: 55–89
   PubMed Web of Science ®Google Scholar
• Sastre-Coll A, Esteban S, Miralles A, Zanetti R, Garcia-Sevilla JA. The imidazoline receptor ligand 2-(2-benzofuranyl)-2-imidazoline is a dopamine-releasing agent in the rat striatum in vivo. Neurosci Lett 2001; 301. 32
   PubMed Web of Science ®Google Scholar
• Sastre M, Escriba PV, Reis DJ, Garcia-Sevilla JA. Decreased number and immunoreactivity of I2-imidazoline receptors in the frontal cortex of suicide victims. Ann NY Acad Sci 1995; 763: 520–522
   PubMedGoogle Scholar
• Sautter FJ, Bissette G, Wiley J, Manguno-Mire G, Schoenbachler B, Myers L, Johnson JE, Cerbone A, Malaspina D. Corticotropin-releasing factor in posttraumatic stress disorder (PTSD) with secondary psychotic symptoms, nonpsychotic PTSD, and healthy control subjects. Biol Psychiatry 2003; 54: 1382–1388
   PubMed Web of Science ®Google Scholar
• Schelling G, Kilger E, Roozendaal B, de Quervain DJ, Briegel J, Dagge A, Rothenhausler HB, Krauseneck T, Nollert G, Kapfhammer HP. Stress doses of hydrocortisone, traumatic memories, and symptoms of posttraumatic stress disorder in patients after cardiac surgery: A randomized study. Biol Psychiatry 2004; 55: 627–633
   PubMed Web of Science ®Google Scholar
• Schmidt U, Frerick H, Kraft K, Schenk N, Löw-Kröger A. Hypertension: A possible risk in road traffic. J Cardiovasc Pharmacol 1992; 20: S50–S56
   PubMed Web of Science ®Google Scholar
• Scott LV, Dinan TG. Vasopressin and the regulation of hypothalamic–pituitary–adrenal axis function: Implications for the pathophysiology of depression. Life Sci 1998; 62: 1985–1998
   PubMed Web of Science ®Google Scholar
• Separovic D, Kester M, Ernsberger P. Coupling of I1-imidazoline receptors to diacylglyceride accumulation in PC12 rat pheochromocytoma cells. Mol Pharmacol 1996; 49: 668–675
   PubMed Web of Science ®Google Scholar
• Separovic D, Kester M, Haxhiu MA, Ernsberger P. Activation of phosphatidylcholine-selective phospholipase C by I1-imidazoline receptors in PC12 cells and rostral ventrolateral medulla. Brain Res 1997; 749: 335–339
   PubMed Web of Science ®Google Scholar
• Silverman AJ, Hou-Yu A, Chen WP. Corticotropin-releasing factor synapses within the paraventricular nucleus of the hypothalamus. Neuroendocrinology 1989; 49: 291–299
   PubMed Web of Science ®Google Scholar
• Smoller JW, Yamaki LH, Fagerness JA, Biederman J, Racette S, Laird NM, Kagan J, Snidman N, Faraone SV, Hirshfeld-Becker D, Tsuang MT, Slaugenhaupt SA, Rosenbaum JF, Sklar PB. The corticotropin-releasing hormone gene and behavioral inhibition in children at risk for panic disorder. Biol Psychiatry 2005; 57: 1485–1492
   PubMed Web of Science ®Google Scholar
• Soravia LM, Heinrichs M, Aerni A, Maroni C, Schelling G, Ehlert U, Roozendaal B, de Quervain DJ. Glucocorticoids reduce phobic fear in humans. Proc Natl Acad Sci USA 2006; 103: 5585–5590
   PubMed Web of Science ®Google Scholar
• Squires PE, Hills CE, Rogers GJ, Garland P, Farley SR, Morgan NG. The putative imidazoline receptor agonist, harmane, promotes intracellular calcium mobilisation in pancreatic beta-cells. Eur J Pharmacol 2004; 501: 31–39
   PubMed Web of Science ®Google Scholar
• Sun Z, Chang CH, Ernsberger P. Identification of IRAS/Nischarin as an I1-imidazoline receptor in PC12 rat pheochromocytoma cells. J Neurochem 2007; 101: 99–108
   PubMed Web of Science ®Google Scholar
• Swanson LW, Sawchenko PE, Rivier J, Vale WW. Organization of ovine corticotropin-releasing factor immunoreactive cells and fibers in the rat brain: An immunohistochemical study. Neuroendocrinology 1983; 36: 165–186
   PubMed Web of Science ®Google Scholar
• Szabo B, Urban R. Mechanism of sympathoinhibition by imidazolines. Ann NY Acad Sci 1995; 763: 552–565
   PubMedGoogle Scholar
• Szabo B. Imidazoline antihypertensive drugs: A critical review on their mechanism of action. Pharmacol Ther 2002; 93: 1–35
   PubMed Web of Science ®Google Scholar
• Takada K, Hayashi Y, Kamibayashi T, Mammoto T, Yamatodani A, Kitamura S, Yoshiya I. The involvement of pertussis toxin-sensitive G proteins in the post receptor mechanism of central I1-imidazoline receptors. Br J Pharmacol 1997; 120: 1575–1581
   PubMed Web of Science ®Google Scholar
• Talalaenko AN, Krivobok GK, Pankrat'ev DV, Goncharenko NV. Neurochemical mechanisms of the dorsal pallidum in the antiaversive effects of anxiolytics in various models of anxiety. Neurosci Behav Physiol 2006; 36: 749–754
   PubMedGoogle Scholar
• Teixeira de Castro RR, Tibirica E, de Oliveira MA, Moreira PB, Catelli MF, Rocha MN, Nobrega AC. Reduced hemodynamic responses to physical and mental stress under low-dose rilmenidine in healthy subjects. Cardiovasc Drugs Ther 2006; 20: 129–134
   PubMed Web of Science ®Google Scholar
• Tesson F, Limon-Boulez I, Urban P, Puype M, Vandekerckhove J, Coupry I, Pompon D, Parini A. Localization of I2-imidazoline binding sites on monoamine oxidases. J Biol Chem 1995; 270: 9856–9861
   PubMed Web of Science ®Google Scholar
• Thomas B, Prell GD. Imidazoleacetic acid, a gamma-aminobutyric acid receptor agonist, can be formed in rat brain by oxidation of histamine. J Neurochem 1995; 65: 818–826
   PubMed Web of Science ®Google Scholar
• Thomson F, Craighead M. Innovative approaches for the treatment of depression: Targeting the HPA axis. Neurochem Res 2007
   PubMed Web of Science ®Google Scholar
• Tibirica E, Mermet C, Feldman J, Gonon F, Bousquet P. Correlation between the inhibitory effect on catecholaminergic ventrolateral medullary neurons and the hypotension evoked by clonidine: A voltammetric approach. J Pharmacol Exp Ther 1989; 250: 642–647
   PubMed Web of Science ®Google Scholar
• Touiki K, Rat P, Molimard R, Chait A, de Beaurepaire R. Harmane inhibits serotonergic dorsal raphe neurons in the rat. Psychopharmacology (Berl) 2005; 182: 562–569
   PubMed Web of Science ®Google Scholar
• Tunnicliff G. Pharmacology and function of imidazole 4-acetic acid in brain. Gen Pharmacol 1998; 31: 503–509
   PubMedGoogle Scholar
• Ugedo L, Pineda J, Ruiz-Ortega JA, Martin-Ruiz R. Stimulation of locus coeruleus neurons by non-I1/I2-type imidazoline receptors: An in vivo and in vitro electrophysiological study. Br J Pharmacol 1998; 125: 1685–1694
   PubMed Web of Science ®Google Scholar
• Ugedo L, Pineda J, Martin-Ruiz R, Ruiz-Ortega JA, Artigas F. Imidazoline-induced inhibition of firing rate of 5-HT neurons in rat dorsal raphe by modulation of extracellular 5-HT levels. Ann NY Acad Sci 1999; 881: 365–368
   PubMed Web of Science ®Google Scholar
• Valentino RJ, Curtis AL. Pharmacology of locus coeruleus spontaneous and sensory-evoked activity. Prog Brain Res 1991; 88: 249–256
   PubMed Web of Science ®Google Scholar
• Van Den Eede F, Van Broeckhoven C, Claes SJ. Corticotropin-releasing factor-binding protein, stress and major depression. Ageing Res Rev 2005; 4: 213–239
   PubMed Web of Science ®Google Scholar
• Wang LG, Gao L, Wang W, Yuan WJ, Wang WZ. Sympathoexcitation of moxonidine in the caudal ventrolateral medulla is dependent on I1-imidazoline receptors in anesthetized rats. Neurosci Lett 2007; 426: 91–96
   PubMed Web of Science ®Google Scholar
• Welch JE, Saphier D. Central and peripheral mechanisms in the stimulation of adrenocortical secretion by the 5-hydroxytryptamine2 agonist, (+)-1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane. J Pharmacol Exp Ther 1994; 270: 918–928
   PubMed Web of Science ®Google Scholar
• Welch JE, Farrar GE, Dunn AJ, Saphier D. Central 5-HT1A receptors inhibit adrenocortical secretion. Neuroendocrinology 1993; 57: 272–281
   PubMed Web of Science ®Google Scholar
• Wenzel RR, Mitchell A, Siffert W, Buhrmann S, Philipp T, Schafers RF. The I1-imidazoline agonist moxonidine decreases sympathetic tone under physical and mental stress. Br J Clin Pharmacol 2004; 57: 545–551
   PubMed Web of Science ®Google Scholar
• Wolkowitz OM, Reus VI, Chan T, Manfredi F, Raum W, Johnson R, Canick J. Antiglucocorticoid treatment of depression: Double-blind ketoconazole. Biol Psychiatry 1999; 45: 1070–1074
   PubMed Web of Science ®Google Scholar
• Yang YL, Chao PK, Lu KT. Systemic and intra-amygdala administration of glucocorticoid agonist and antagonist modulate extinction of conditioned fear. Neuropsychopharmacology 2006; 31: 912–924
   PubMed Web of Science ®Google Scholar
• Yehuda R, Yang RK, Buchsbaum MS, Golier JA. Alterations in cortisol negative feedback inhibition as examined using the ACTH response to cortisol administration in PTSD. Psychoneuroendocrinology 2006; 31: 447–451
   PubMed Web of Science ®Google Scholar
• Yu YW, Tsai SJ, Hong CJ, Chen TJ, Chen MC, Yang CW. Association study of a monoamine oxidase a gene promoter polymorphism with major depressive disorder and antidepressant response. Neuropsychopharmacology 2005; 30: 1719–1723
   PubMed Web of Science ®Google Scholar
• Zacharko RM, Anisman H. Stressor-induced anhedonia in the mesocorticolimbic system. Neurosci Biobehav Rev 1991; 15: 391–405
   PubMed Web of Science ®Google Scholar
• Zeidan MP, Zomkowski AD, Rosa AO, Rodrigues AL, Gabilan NH. Evidence for imidazoline receptors involvement in the agmatine antidepressant-like effect in the forced swimming test. Eur J Pharmacol 2007; 565: 125–131
   PubMed Web of Science ®Google Scholar
• Zhang J, Abdel-Rahman AA. Mitogen-activated protein kinase phosphorylation in the rostral ventrolateral medulla plays a key role in imidazoline (i1)-receptor-mediated hypotension. J Pharmacol Exp Ther 2005; 314: 945–952
   PubMed Web of Science ®Google Scholar
• Zhang J, Abdel-Rahman AA. Nischarin as a functional imidazoline (I1) receptor. FEBS Lett 2006; 580: 3070–3074
   PubMed Web of Science ®Google Scholar
• Zhang J, El-Mas MM, Abdel-Rahman AA. Imidazoline I(1) receptor-induced activation of phosphatidylcholine-specific phospholipase C elicits mitogen-activated protein kinase phosphorylation in PC12 cells. Eur J Pharmacol 2001; 415: 117–125
   PubMed Web of Science ®Google Scholar
• Zhu H, Halaris A, Piletz JE. Chronic imipramine treatment downregulates IR1-imidazoline receptors in rat brainstem. Life Sci 1997a; 61: 1973–1983
   Google Scholar
• Zhu H, Paul IA, McNamara M, Redmond A, Nowak G, Piletz JE. Chronic imipramine treatment upregulates IR2-imidazoline receptive sites in rat brain. Neurochem Int 1997b; 30: 101–107
   PubMed Web of Science ®Google Scholar
• Zhu H, Halaris A, Madakasira S, Pazzaglia P, Goldman N, DeVane CL, Andrew M, Reis D, Piletz JE. Effect of bupropion on immunodensity of putative imidazoline receptors on platelets of depressed patients. J Psychiatr Res 1999; 33: 323–333
   PubMed Web of Science ®Google Scholar
• Zhu H, Hayes J, Chen M, Baldwin J, Piletz JE. Relationship between platelet imidazoline receptor-binding peptides and candidate imidazoline-1 receptor, IRAS. Ann NY Acad Sci 2003; 1009: 439–446
   PubMed Web of Science ®Google Scholar
• Zobel AW, Nickel T, Kunzel HE, Ackl N, Sonntag A, Ising M, Holsboer F. Effects of the high-affinity corticotropin-releasing hormone receptor 1 antagonist R12 in major depression: The first 20 patients treated. J Psychiatr Res 2000; 34: 171–181
   PubMed Web of Science ®Google Scholar
• Zobel AW, Nickel T, Sonntag A, Uhr M, Holsboer F, Ising M. Cortisol response in the combined dexamethasone/CRH test as predictor of relapse in patients with remitted depression. a prospective study. J Psychiatr Res 2001; 35: 83–94
   PubMed Web of Science ®Google Scholar
• Zomkowski AD, Hammes L, Lin J, Calixto JB, Santos AR, Rodrigues AL. Agmatine produces antidepressant-like effects in two models of depression in mice. Neuroreport 2002; 13: 387–391
   PubMed Web of Science ®Google Scholar